Irelli Azzurra, Ceriello Laura, Patruno Leonardo Valerio, Tessitore Alessandra, Alesse Edoardo, Cannita Katia, Fabiani Donatello
Medical Oncology Unit, Department of Oncology, "Giuseppe Mazzini" Hospital, AUSL 04 Teramo, 64100 Teramo, Italy.
Cardiology Unit, Department of Cardiovascular Diseases, "Giuseppe Mazzini" Hospital, AUSL 04 Teramo, 64100 Teramo, Italy.
Biomedicines. 2024 Jan 14;12(1):179. doi: 10.3390/biomedicines12010179.
Pertuzumab and trastuzumab have been shown to improve the outcomes of patients with metastatic breast cancer, with a rate of left ventricular dysfunction of approximately 6%. We report the case of a postmenopausal woman who presented with Takotsubo syndrome during maintenance therapy with pertuzumab and trastuzumab, in association with fulvestrant (an anti-estrogen) and denosumab. After normalization of cardiac function, therapy with pertuzumab and trastuzumab was resumed in the absence of new cardiac toxicity. We report the first clinical case of Takotsubo syndrome during double anti-HER2 blockade in association with an antiestrogen. Furthermore, we show how anti-HER2 therapy can be safely resumed after the detection of Takotsubo syndrome.
帕妥珠单抗和曲妥珠单抗已被证明可改善转移性乳腺癌患者的预后，左心室功能障碍发生率约为6%。我们报告了一例绝经后女性病例，该患者在接受帕妥珠单抗、曲妥珠单抗联合氟维司群（一种抗雌激素药物）和地诺单抗维持治疗期间出现了Takotsubo综合征。在心脏功能恢复正常后，在没有新的心脏毒性的情况下恢复了帕妥珠单抗和曲妥珠单抗治疗。我们报告了首例在双重抗HER2阻断联合抗雌激素治疗期间发生Takotsubo综合征的临床病例。此外，我们展示了在检测到Takotsubo综合征后如何安全地恢复抗HER2治疗。
